Novartis Pharmaceuticals

This early-phase study tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer that had certain genetic changes. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This study tested the drug iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if it could improve platelet counts in ITP or hemoglobin levels in CAD. The study was terminated early, so results ar…

This study tested a medicine called ensovibep in adults with mild-to-moderate COVID-19 who were not in the hospital. The goal was to see if it could lower the amount of virus in the body and reduce the need for hospital care. About 400 people took part, but the study was stopped …

This early-phase study tested a new type of immunotherapy called CAR-T cells that target a protein called BCMA on myeloma cells. The treatment involved taking a patient's own immune cells, engineering them to attack the cancer, and giving them back. The study aimed to check safet…

This early-phase study aimed to find safe doses of drug combinations for adults with lower-risk myelodysplastic syndrome (MDS), a blood disorder. Researchers enrolled 33 participants to check for side effects and how well the drugs were tolerated. The study was terminated early, …

This study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe. The goal was to see if the drug could improve blood flow and exercise ability. The study was …

This study tested the drug capmatinib given before and after surgery for people with a certain type of non-small cell lung cancer that has a MET gene change. The goal was to see if the drug could shrink tumors before surgery and help prevent cancer from coming back. However, the …

This study looked at the long-term safety of an experimental drug called LTP001 for people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. It was an open-label extension, meaning everyone knew they were getting the drug. The stu…

This study tested whether anti-inflammatory drugs could help people with early Alzheimer's or mild cognitive impairment. The trial was stopped early, so only one drug was tested in 34 participants. The goal was to see if the drug improved thinking and memory, but the early end me…

This early-phase study tested a new drug called FAZ053, which helps the immune system fight cancer, given alone or with another drug (PDR001) in 154 adults with advanced solid tumors (including triple-negative breast cancer and rare sarcomas). The main goal was to check safety an…

This study tested a new drug called XXB750 in 136 people with heart failure and reduced heart function. The goal was to see if the drug could lower a marker of heart strain (NT-proBNP) and was safe. The trial was stopped early, so results are limited.

This early-phase study tested two experimental drugs, VOB560 and MIK665, together in 37 people with relapsed or refractory non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma. The goal was to find safe doses and see if the combination could kill cancer cells by bloc…

This study tested an experimental drug called QBW251 in 42 adults with bronchiectasis, a lung condition that causes mucus buildup and infections. The goal was to see if the drug could reduce bacteria in the lungs and improve symptoms like coughing and shortness of breath. The tri…

This study tested an experimental drug called LNA043, given as a shot into the knee, to see if it could slow down cartilage loss and reduce pain in people with knee osteoarthritis. The trial planned to follow 576 adults aged 40 to 75 for up to 5 years, but it was stopped early. T…

This study tested a new drug called sabatolimab added to standard chemotherapy for people with intermediate to very high risk myelodysplastic syndrome (MDS), a type of blood cancer. The main goal was to check safety and side effects. A total of 39 adults took part, but the study …

This study tested whether adding the drug alpelisib to standard chemotherapy (nab-paclitaxel) could help people with advanced triple negative breast cancer that has specific genetic changes (PIK3CA mutation or PTEN loss). The trial enrolled 137 participants but was stopped early.…

This early-phase study tested an experimental drug called QEQ278 in 30 adults with advanced solid tumors, including lung, kidney, esophageal, and head and neck cancers. The main goal was to check the drug's safety and find the right dose. The trial was terminated early, so result…

This study tested a new, easy-to-take malaria tablet for infants and newborns weighing less than 5 kg who had uncomplicated malaria. The goal was to see if the medicine was safe and worked well in this very young group. The study was stopped early, but the information gathered he…

This early-stage study tested two new drug combinations (HDM201 with MBG453 or venetoclax) in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The main goal was to check safety and find the right dose. The study was stopped early, so results a…

This early-phase study tested a new drug combination (ribociclib plus topotecan and temozolomide) in children and young adults with relapsed or hard-to-treat neuroblastoma and other solid tumors. The goal was to find a safe dose and see if it could shrink tumors. Only 12 people t…

This study tested a new drug called sabatolimab combined with two standard treatments (azacitidine and venetoclax) in 20 adults with high-risk myelodysplastic syndromes (MDS) who could not have intensive chemotherapy or a stem cell transplant. The goal was to see if the combinati…

This study tested new single treatments for idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. It enrolled 46 adults aged 40 and older with stable IPF. The study was terminated early, and results are not yet available.

This study tested a new drug (MBG453) combined with two other medicines (azacitidine and venetoclax) for adults with acute myeloid leukemia who were too frail for standard chemotherapy. The goal was to see if the combination was safe and could lead to remission. The trial was ter…

This study tested whether adding the experimental drug MBG453 to standard chemotherapy (azacitidine) helps people with high-risk myelodysplastic syndrome (MDS) or a related leukemia (CMML-2) live longer. About 530 adults who could not have intensive chemo or a stem cell transplan…

This early-stage study tested a drug called VAY736, alone or with other cancer drugs, in 18 adults with certain types of Non-Hodgkin lymphoma that had come back or not responded to standard treatments. The main goal was to check safety and find the right dose. The study was stopp…

This early-phase study tested a one-time treatment using the patient's own genetically modified stem cells to boost fetal hemoglobin, which can reduce painful crises and other severe complications of sickle cell disease. Only 4 participants were enrolled before the study was term…

This early-stage study tested a new drug called WVT078, alone or with another drug (WHG626), in 56 people whose multiple myeloma had returned or stopped responding to at least two prior treatments. The main goal was to find a safe dose and check for side effects. The study was te…

This study tested whether adding the experimental drug NIS793 (with or without another drug, spartalizumab) to standard chemotherapy could help people with metastatic pancreatic cancer that had not been treated before. The trial was stopped early, so results are limited. It invol…

This study tested whether adding an immunotherapy drug (PDR001) to two standard targeted therapies (dabrafenib and trametinib) could help people with advanced melanoma that has a specific gene change (BRAF V600). The trial was stopped early and did not reach its main goals. About…

This study tested whether adding canakinumab to standard immunotherapy (pembrolizumab) and chemotherapy could help people with advanced non-small cell lung cancer live longer or slow tumor growth. The trial enrolled 673 adults who had not received prior treatment. The study was t…

This study tested a new treatment called PHE885 for adults with multiple myeloma that came back or didn't respond to at least three prior therapies. PHE885 is a type of CAR-T cell therapy that targets a protein called BCMA on myeloma cells. The goal was to see how well it shrinks…

This study aimed to monitor side effects, especially high blood sugar, in people with a certain type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) taking alpelisib plus fulvestrant. It was designed for postmenopausal women and men whose cancer had worsened after …

This study tested a drug called TIN816 to see if it could prevent acute kidney injury in adults after heart surgery. About 102 people were planned to take part, but the study was stopped early. The goal was to measure kidney function using a blood test called serum creatinine.

This study tested a drug called secukinumab for people with active, moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. The trial aimed to see if the drug could reduce eye swelling and bulging over 16 weeks. However, the study was stopped e…

This study followed 6 adults with PNH who were already taking iptacopan as part of their normal care in Russia. Researchers tracked whether their hemoglobin levels improved and if they needed fewer blood transfusions over 6 to 12 months. The study was stopped early, so results ar…

This study tested an experimental drug called MBG453 added to standard chemotherapy for people with intermediate to very high-risk myelodysplastic syndrome (MDS) who could not have a stem cell transplant. The goal was to see if the combination could improve remission rates and de…

This early-stage study tested a new drug called JBH492 in 25 people with chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL) whose cancer had returned or stopped responding to prior treatments. The main goal was to check the drug's safety and find the right dose. T…

This study tested whether combining two drugs, alpelisib and olaparib, works better than standard chemotherapy for people with a certain type of advanced ovarian cancer that no longer responds to platinum-based chemo. The trial included 358 adults whose cancer had returned or res…

This early-phase study tested a new drug called 177Lu-FF58, which delivers radiation directly to cancer cells that have specific markers (integrins). The goal was to check safety, find the right dose, and see if it shrinks tumors in people with advanced pancreatic, stomach, or br…

This early-stage study tested a new drug called DFF332 in people with advanced clear cell kidney cancer. The drug works by blocking a protein (HIF2α) that helps some cancers grow. Researchers gave DFF332 alone or with other drugs to see if it was safe and could shrink tumors. The…

This study checked the long-term safety of ligelizumab, an investigational drug for food allergy. It included 163 people who had already finished a phase 3 study on ligelizumab. The main goal was to track side effects over three years.

This early-phase study tested different drug combinations in 122 adults with advanced or metastatic BRAF V600 colorectal cancer. The main goal was to understand safety, side effects, and find the best doses for future studies. The trial was terminated, but the results help guide …

This early-stage study tested an experimental oral drug called TNO155 in 227 adults with advanced solid tumors (like lung, skin, or esophageal cancer) that had stopped responding to standard treatments. The main goal was to find safe doses and understand side effects, both when g…

This early-stage trial tested a new drug (TNO155) combined with either spartalizumab or ribociclib in adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The main goal was to check safety and find the right dose. The study was terminated, so result…

This study tested a drug called sabatolimab in 24 adults and teens with acute myeloid leukemia who still had small amounts of cancer cells after a stem cell transplant. The goal was to see if sabatolimab, alone or with another drug, could prevent the leukemia from coming back wit…

This study tested a new radioactive imaging agent called [68Ga]-FF58 to see how well it could detect certain solid tumors, including glioblastoma, breast cancer that spread to the brain, gastroesophageal cancer, and pancreatic cancer. The study was early-phase and involved 14 adu…

This study tested whether secukinumab (a drug that targets inflammation) could reduce pain and improve shoulder function in adults with moderate to severe rotator cuff tendinopathy. Participants received either the drug or a placebo, plus standard care, for 24 weeks. The study wa…

This study tested an experimental drug called MIJ821, given as an IV infusion, in addition to standard care for people with major depression who were having active suicidal thoughts. The goal was to see if it could quickly reduce depression symptoms. The trial involved 199 adults…

This study tested an experimental drug called QUC398 in 101 people with painful knee osteoarthritis. The goal was to see if it could reduce pain and protect knee cartilage. The trial was stopped early, so results are limited.

This study aimed to see how satisfied people with migraine were after starting a new medication called erenumab. It followed 37 adults in the Gulf region for 12 weeks, asking them to rate their treatment satisfaction. The study was terminated early, so results are limited.

This study tested a chewable tablet called fevipiprant in children aged 6 to 12 with asthma. The goal was to measure how the drug moves through the body and check its safety. Only 11 children took part before the study was stopped early.

This study tested two drugs, canakinumab and LNA043, injected into the knee to see if they could ease pain and protect cartilage in people with knee osteoarthritis. It included 23 adults with moderate to severe knee pain. The study was terminated early, so results are limited.

This study tested whether secukinumab, an injected drug, could reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy (shoulder tendon pain). About 60 people were planned to receive either the drug or a placebo for 24 weeks. The trial was ter…

This study aimed to confirm if two simple blood test results—hemoglobin below 15.5 g/dL and a high red blood cell distribution width—could predict which patients with polycythemia vera would not respond well to the drug hydroxyurea. Researchers planned to follow 76 adults startin…

This study looked at whether the drug BLZ945 is safe and how it affects brain inflammation in people with ALS. Researchers used special PET scans to measure immune cell activity in the brain. The study was stopped early, and it involved 28 adults with ALS.